212Pb-DOTAMTATE (212Pb-AlphaMedix™) is a somatostatin analogue labeled with Lead-212 and developed for the treatment of patients with somatostatin receptor positive neuroendocrine tumors. On November 13, 2018, 212Pb-AR-RMX received Orphan Drug status for NET from FDA. DOTAM is a specific chelating agent with a structure similar to TCMC and actually not so close to the much well known DOTA.
The profile, in terms of targeted indications, of this drug is similar to 177Lu-Oxodotreotide, with the additional advantage that the decay products of 212Pb are alpha emitters. Therefore, it adds the alpha emission activity to the beta activity of Lutetium-177, providing these alpha-emitters are decaying in the vicinity of the tumor cells.
A first clinical trial performed with the 203Pb analogue demonstrated that the marketed 68Ga-DOTATATE would be similarly efficient to identify the patient eligible for treatment with 212Pb-AlphaMedix than the 203Pb labeled imaging agent. As a consequence, the development of the 203Pb analogue was put on hold.
The potential indications cover all neuroendocrine tumors (NET) and the development will probably target the NET patients that were non-responders to beta-emitters.
A Phase I trial has been initiated in January 2018 with the aim to assess the safety and dose limiting toxicity of the drug and to determine its pharmacokinetic properties and preliminary effectiveness. A Phase II trial was initiated in January 2022.
Target/Mechanism: somatostatin receptors
Radiation Type: alpha particle (α)